Fortress Biotech, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Investments at Fair Value (Tables)

Investments at Fair Value (Tables)

6 Months Ended

Jun. 30, 2015

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following tables classify into the fair value hierarchy financial instruments measured at fair value on a recurring basis in the accompanying Condensed Consolidated Balance Sheets as of June 30, 2015 (unaudited) and December 31, 2014:

	Fair Value Measurement as of June 30, 2015
($ in thousands)	Level 1		Level 2		Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	20,000	$	-	$	-	$	20,000
Total marketable securities		20,000		-		-		20,000
Long-term investments, at fair value		-		-		5,567		5,567
Total	$	20,000	$	-	$	5,567	$	25,567

	Fair Value Measurement as of December 31, 2014
($ in thousands)	Level 1		Level 2		Level 3		Total
Assets
Marketable securities:
U.S. treasury bills	$	19,998	$	-	$	-	$	19,998
Mutual funds		4		-				4
Total marketable securities		20,002		-		-		20,002
Long-term investments, at fair value		-		-		4,160		4,160
Total	$	20,002	$	-	$	4,160	$	24,162

Schedule of changes in fair value of financial instruments

The table below provides a roll-forward of the changes in fair value of Level 3 financial instruments, as of June 30, 2015:

($ in thousands)	Other		CB Pharma		Total
Balance at December 31, 2014	$	250	$	3,910	$	4,160
Purchases		-		-		-
Change in fair value of investment		-		1,407		1,407
Balance at June 30, 2015	$	250	$	5,317	$	5,567